Literature DB >> 32179954

[Aggressive dose de-escalation in adjuvant therapy for HPV-associated oropharyngeal cancer. Is half of everything enough?]

Markus Hecht1, Sabine Semrau2.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32179954     DOI： 10.1007/s00066-020-01602-2

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  4 in total

1.  Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.

Authors:  Maura L Gillison; Andy M Trotti; Jonathan Harris; Avraham Eisbruch; Paul M Harari; David J Adelstein; Richard C K Jordan; Weiqiang Zhao; Erich M Sturgis; Barbara Burtness; John A Ridge; Jolie Ringash; James Galvin; Min Yao; Shlomo A Koyfman; Dukagjin M Blakaj; Mohammed A Razaq; A Dimitrios Colevas; Jonathan J Beitler; Christopher U Jones; Neal E Dunlap; Samantha A Seaward; Sharon Spencer; Thomas J Galloway; Jack Phan; James J Dignam; Quynh Thu Le
Journal:  Lancet       Date:  2018-11-15       Impact factor: 79.321

2.  Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma.

Authors:  Daniel J Ma; Katharine A Price; Eric J Moore; Samir H Patel; Michael L Hinni; Joaquin J Garcia; Darlene E Graner; Nathan R Foster; Brenda Ginos; Michelle Neben-Wittich; Yolanda I Garces; Ashish V Chintakuntlawar; Daniel L Price; Kerry D Olsen; Kathryn M Van Abel; Jan L Kasperbauer; Jeffrey R Janus; Mark Waddle; Robert Miller; Satomi Shiraishi; Robert L Foote
Journal:  J Clin Oncol       Date:  2019-06-04       Impact factor: 44.544

3.  Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial.

Authors:  Anthony C Nichols; Julie Theurer; Eitan Prisman; Nancy Read; Eric Berthelet; Eric Tran; Kevin Fung; John R de Almeida; Andrew Bayley; David P Goldstein; Michael Hier; Khalil Sultanem; Keith Richardson; Alex Mlynarek; Suren Krishnan; Hien Le; John Yoo; S Danielle MacNeil; Eric Winquist; J Alex Hammond; Varagur Venkatesan; Sara Kuruvilla; Andrew Warner; Sylvia Mitchell; Jeff Chen; Martin Corsten; Stephanie Johnson-Obaseki; Libni Eapen; Michael Odell; Christina Parker; Bret Wehrli; Keith Kwan; David A Palma
Journal:  Lancet Oncol       Date:  2019-08-12       Impact factor: 41.316

4.  Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.

Authors:  Hisham Mehanna; Max Robinson; Andrew Hartley; Anthony Kong; Bernadette Foran; Tessa Fulton-Lieuw; Matthew Dalby; Pankaj Mistry; Mehmet Sen; Lorcan O'Toole; Hoda Al Booz; Karen Dyker; Rafael Moleron; Stephen Whitaker; Sinead Brennan; Audrey Cook; Matthew Griffin; Eleanor Aynsley; Martin Rolles; Emma De Winton; Andrew Chan; Devraj Srinivasan; Ioanna Nixon; Joanne Grumett; C René Leemans; Jan Buter; Julia Henderson; Kevin Harrington; Christopher McConkey; Alastair Gray; Janet Dunn
Journal:  Lancet       Date:  2018-11-15       Impact factor: 79.321
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.